Lumacaftor/ivacaftor (Orkambi®, LUM/IVA) is indicated for the treatment of cystic fibrosis (CF) patients aged ≥ 2 years with homozygous F580del mutation in the CFTR gene. Triazole fungal agents are used to treat fungal disease in CF. The use of triazoles is limited by pharmacokinetic challenges, such as drug-drug interactions. The most notable drug-drug interaction between triazoles and LUM/IVA is due to strong induction of CYP3A4 and UGT by LUM. In this real-world retrospective observational study, we described the effect of LUM/IVA on the trough concentration of triazoles. Concomitant use of LUM/IVA with itraconazole, posaconazole or voriconazole resulted in subtherapeutic triazole levels in 76% of the plasma samples. In comparison, in patients with triazole agents without LUM/IVA only 30.6% of the plasma samples resulted in subtherapeutic concentrations. Subtherapeutic plasma concentrations of triazoles should be considered in CF patients on LUM/IVA and further research is warranted for other dosing strategies and alternative antifungal therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcf.2024.01.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of inflammation on voriconazole levels in patients with invasive pulmonary aspergillosis.
J Infect Dev Ctries
October 2024
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Article Synopsis
- Voriconazole (VCZ) serum concentrations can be influenced by various factors, and this study explores its levels in patients with COVID-19-associated aspergillosis (CAPA) and invasive pulmonary aspergillosis (IPA).
- The study included 85 patients, finding that about 50.6% had VCZ levels in the therapeutic range, while a significant number had either sub-therapeutic or supra-therapeutic levels, with inflammation markers notably higher in those with supra-therapeutic levels.
- CAPA patients showed a higher incidence of adverse effects and elevated VCZ levels compared to IPA patients, highlighting the need for more frequent monitoring of VCZ in this group.
Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction.
Antimicrob Agents Chemother
November 2024
Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Article Synopsis
- This study investigates how voriconazole (VRC) levels are distributed in patients with liver dysfunction, emphasizing the need for careful monitoring of drug levels in this population.
- It analyzes medical records of 102 hospitalized patients and identifies factors like age, liver disease severity (Child-Pugh score), CRP levels, and bilirubin that affect VRC concentrations.
- The findings suggest a high rate of VRC-related side effects and propose that dosage adjustments, including therapeutic drug monitoring, are crucial for older patients and those with severe infections or low albumin levels to avoid toxicity.
Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug-Drug Interaction Between Voriconazole and Flucloxacillin.
Eur J Drug Metab Pharmacokinet
November 2024
Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Background And Objectives: Voriconazole administered concomitantly with flucloxacillin may result in subtherapeutic plasma concentrations as shown in a patient with Staphylococcus aureus sepsis and a probable pulmonary aspergillosis. After switching our patient to posaconazole, therapeutic concentrations were reached. The aim of this study was to first test our hypothesis that flucloxacillin competes with voriconazole not posaconazole for binding to albumin ex vivo, leading to lower total concentrations in plasma.
View Article and Find Full Text PDFEvaluation of Empiric Voriconazole Dosing and Therapeutic Drug Monitoring in Hospitalized Pediatric Patients.
J Pediatr Hematol Oncol
August 2024
Department of Pharmacy, Children's Hospital Colorado, Aurora, CO.
Invasive fungal infections are a significant cause of morbidity and mortality in children with immunodeficiencies. Current dosing recommendations for voriconazole often result in subtherapeutic exposure in pediatric patients. In this single-center retrospective study, we reviewed hospitalized pediatric patients receiving voriconazole with at least one inpatient serum trough concentration measured.
View Article and Find Full Text PDFBreakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
Clin Infect Dis
July 2024
Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Background: Primary antifungal prophylaxis with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treatment failure are still not fully understood. To help inform clinical decisions, we sought to define microbiological, clinical, and pharmacological characteristics of proven and probable breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological disorders receiving voriconazole or posaconazole prophylaxis.
Methods: We performed a systematic review of the literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!